The next chapter of incretin-based therapy for lowering cardiovascular risk in type 2 diabetes will be represented, most likely, by the development of tri-agonists capable of simultaneous activation of GLP-1, GIP and glucagon receptors. This evidence concerns the gene GIP and type 2 diabetes mellitus.